We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
20th Sep 201712:02 pmRNSPrice Monitoring Extension
13th Sep 201712:07 pmRNSSecond Price Monitoring Extn
13th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 20171:30 pmRNSFurther Strengthens US Patent Estate
8th Sep 201712:07 pmRNSSecond Price Monitoring Extn
8th Sep 201712:02 pmRNSPrice Monitoring Extension
6th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
4th Sep 20177:00 amRNSNotice of Interim Results
23rd Aug 20177:00 amRNSSave the Date: Capital Markets Event 14 November
17th Aug 20174:05 pmRNSReplacement - Holding(s) in Company
17th Aug 20172:02 pmRNSDirector/PDMR Shareholding
15th Aug 20177:00 amRNSTwo further US patents to be granted
3rd Aug 20177:00 amRNSDirector/PDMR Shareholding
31st Jul 201711:43 amRNSDirector/PDMR Shareholding
31st Jul 20177:00 amRNSHolding(s) in Company
31st Jul 20177:00 amRNSUS patent to be granted
27th Jul 20172:43 pmRNSLicensee Quark Announces Positive AKI Results
24th Jul 20177:00 amRNSPresenting at Canaccord Genuity Growth Conference
24th Jul 20177:00 amRNSSilence Strengthens US Patent Estate
14th Jul 20177:00 amRNSCEO Ali Mortazavi appointed Chairman of Ultromics
10th Jul 20177:41 amRNSIP update
3rd Jul 20172:34 pmRNSIssue of claim in the UK High Courts
3rd Jul 20177:00 amRNSChange of Adviser
29th Jun 201711:47 amRNSHolding(s) in Company
6th Jun 20177:00 amRNSResult of AGM
1st Jun 20177:00 amRNSHiring of Chief Operating Officer
30th May 20177:00 amRNSSilence Continued Expansion of IP
16th May 20177:00 amRNSSignificant Expansion of Intellectual Property
4th May 201712:05 pmRNSNotice of AGM and Publication of Annual Report
3rd May 20177:00 amRNSSilence Therapeutics Presents New Data
12th Apr 20171:30 pmRNSAdditional Listing
3rd Apr 20177:00 amRNSGrant of Share Options to Directors
28th Mar 20177:00 amRNSPreliminary Results for the year to 31 Dec 2016
8th Mar 20177:00 amRNSNotice of Results
13th Jan 20172:03 pmRNSMinority Stake in Arrowhead Pharmaceuticals
9th Jan 20177:00 amRNSAcquisition of Minority Stake in Arrowhead
20th Dec 20167:00 amRNSSilence announces Quark arbitration resolution
15th Nov 20167:00 amRNSCRISPR/Cas9 Gene Editing Data
27th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSNotice of Results
5th Sep 20167:00 amRNSAppointment of CSO and Non-Executive Director
18th Jul 20167:00 amRNSDirector/PDMR Shareholding
17th Jun 20163:48 pmRNSResult of AGM
1st Jun 20162:35 pmRNSHolding(s) in Company
24th May 20167:00 amRNSBoard Changes, Advisory Board and Notice of AGM
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
18th Apr 20166:09 pmRNSDirector/PDMR Shareholding
18th Apr 20167:00 amRNSGrant of share options to Chief Executive
5th Apr 20167:00 amRNSAtu027 Update
5th Apr 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.